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quently had a survival advantage of clinical relevance. When tumor 
response was introduced in the Cox model (as a four level variable), the 
difference in Overall Survival between PCG and PC changed from a 
signiﬁcant level (HR=1.28; CI 1.00-1.63; P=0.049) to a not signiﬁcant 
level (HR=0.99; CI: 0.76 - 1.28; P=0.97). 
Conclusions: To our knowledge this is the ﬁrst report showing a sig-
niﬁcant direct correlation between Response and Survival in NSCLC 
according to Prentice criteria.
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Background: ACTION (Assessment of Costs and ouTcomes of 
chemotherapy In an Observational setting in patients with advanced 
NSCLC) is a prospective, pan-European observational study. The ob-
jective of ACTION is to describe advanced NSCLC treatment patterns 
and patient outcomes in routine clinical practice.
Methods: Chemonaive patients (pts) aged ≥ 18 yrs with stage IIIb/IV 
NSCLC were observed for 18 months from presentation for initiation 
of ﬁrst line chemotherapy (CT). All pt care, including CT given, was at 
the discretion of the pt/physician. Pts were excluded if participating in 
a clinical trial. Overall survival was estimated using the Kaplan Meier 
method. Assessment of prognostic factors for survival was performed 
using Cox’s proportional hazards model.
Results: 975 patients were enrolled between April 2003 and Septem-
ber 2004, with observations completed in March 2006. Median age 
was 65 yrs (32-90) with 28.3% of pts aged ≥70 yrs; 71.3% were male; 
65.2% had stage IV disease. Of 487 pts who experienced weight loss, 
172 lost >10% body weight in 4 weeks prior to the start of CT. Overall 
WHO PS at baseline was 0 (21.1%), 1 (65.1%), 2 (10.0%), 3 (3.3%), 4 
(0.5%). One-year survival rate was estimated to be 39.5%. Unadjusted 
median survival time for all pts was 9.3 months (mo) (95% CI 8.6-
10.3), for pts receiving 3rd generation CT [either gemcitabine (gem), 
vinorelbine (vino) or taxane] with a platinum compound as ﬁrst line 
CT: 9.9 mo (8.6 - 10.7), for pts receiving ﬁrst line monotherapy (either 
gem or vino): 9.7 mo (7.3-12.3) and for pts receiving any other CT: 7.9 
mo (6.4-9.3). Assessment of prognostic factors for survival resulted in 
a ﬁnal Cox proportional Hazard model including treatment, WHO PS, 
number of metastatic organs, gender and age as prognostic factors. The 
hazard ratio (HR) for pts with baseline WHO PS 1 vs. PS 0 was 1.224 
(95% HR Conﬁdence Limits 0.994 - 1.509), baseline WHO PS 2 vs. 
PS 0: HR 2.006 (1.466 - 2.745), baseline WHO PS 3/4 vs. PS 0: 2.790 
(1.799 - 4.328). The HR for pts with 1 metastatic organ at baseline vs. 
none was 0.947 (0.777 - 1.154), 2 vs. 0: 1.111 (0.866 - 1.424), 3 vs. 0: 
1.301 (0.870 - 1.944) and 4-6 vs. 0: 3.442 (2.082 - 5.592). For female 
vs. male pts the HR was 0.716 (0.592 - 0.866). The HR for baseline age 
was 0.991 (0.982 - 1.000).
Conclusion: ACTION is the ﬁrst large-scale observational study of 
pts with advanced NSCLC. Median survival is comparable to previ-
ous clinical trial results (e.g. le Chevalier et al, 2005); even though 
the prognosis for these pts indicated that a worse outcome was likely. 
Analysis of factors inﬂuencing survival also reinforce previous clinical 
trial results, as it is seen that gender, baseline WHO PS and disease 
stage signiﬁcantly impact on overall survival, as reported in Schiller et 
al (2002).
A3-03 Cytotoxic Chemotherapy I, Mon, 13:45 - 15:30
Pemetrexed for the treatment of advanced non-small cell lung 
cancer (NSCLC): Results from a randomized phase III dose 
finding trial in patients who progressed following platinum-
containing chemotherapy
Cullen, Michael H.1 Zatloukal, Petr2 Sorenson, Sverre3 Novello, Silvia4 
Fischer, Juergen R.5 Anil Abraham, Joy6 Zereu, Manuela7 Peterson, 
Patrick8 Visseren-Grul, Carla9 Iscoe, Neill10 
1 Cancer Centre at the Queen Elizabeth Hospital, Birmingham, UK 
2 Univerzita Karlova, Prague, Czech Republic 3 University Hospital, 
Linkoping, Sweden 4 University of Turin, Orbassano, Italy 5 Klinik 
Loewenstein, Loewenstein, Germany 6 Cross Cancer Institute, Alberta, 
BC, Canada 7 Santa Casa de Porto Alegre, Porto Alegre, Brazil 8 Eli 
Lilly and Company, Indianapolis, IN, USA 9 Eli Lilly Netherlands, Utre-
cht, The Netherlands 10 Eli Lilly Canada, Danforth, ON, Canada 
Background: Pemetrexed exhibited comparable efﬁcacy and mild 
toxicity in a phase III trial comparing pemetrexed 500 mg/m2 with 
docetaxel 75 mg/m2 in vitamin-supplemented advanced NSCLC 
patients. A second phase III trial was initiated to determine if the peme-
trexed dose could be escalated to increase efﬁcacy, without resulting in 
an unacceptable increase in toxicity.
Methods: Patients with locally advanced or metastatic NSCLC, previ-
ously treated with platinum-based chemotherapy, were randomized to 
iv pemetrexed 500 (P500) or pemetrexed 900 mg/m2 (P900) q 3week. 
The study was terminated after 588 out of 600 patients had enrolled 
since an interim analysis indicated a low probability of a survival ad-
vantage and somewhat greater frequency of toxicity on the P900 arm. 
Patients were allowed to continue treatment at the P500 dose.
Results: Baseline characteristics of patients were balanced on both 
arms: ~67% males, median age 62 yrs, 87% pts with an ECOG PS of 
0 or 1, and 77% pts with stage IV disease. Five hundred eighty-eight 
randomized patients were evaluated for survival; 581 patients, who 
received ≥1 dose, for safety; 509 patients, who received ≥2 cycles and 
had measurable disease, for tumor response. Safety data for patients 
who switched from P900 to P500 were analyzed separately. There was 
no statistical difference between treatment arms for any efﬁcacy mea-
sure: median survival P500 6.7 mo versus P900 6.9 mo, HR=1.0132 
(95% CI 0.837, 1.226); progression-free survival P500 2.6 mo versus 
P900 2.8 mo, HR=0.9681 (95% CI 0.817, 1.147); best overall tumor 
response (all PR) P500 7.1% versus P900 4.3% (p=0.1616). As sum-
marized in the table below, the frequency of Grade 3/4 CTC toxicity 
was somewhat higher in the P900 arm. Likewise, patients on the P900 
arm were hospitalized more frequently for drug-related adverse events 
(P500: 10.7% patients; P900 arm: 15.8% patients), and required more 
blood transfusions (% patients requiring **1 transfusion: P500: 16.9%, 
P900 arm: 20.4%).
